DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alzheimer Disease

Intervention: Aricept (Drug); Exelon (Drug); Nicoderm Patch (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Department of Veterans Affairs

Official(s) and/or principal investigator(s):
Vincente Iragui, M.D., Ph.D
Shuanna Morris, Ph.D.

Summary

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Clinical Details

Official title: Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Eligibility

Minimum age: 55 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e. g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Locations and Contacts

Department of Veterans Affairs, San Diego, California 92161, United States
Additional Information

Starting date: October 1998
Last updated: January 20, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017